WANG-HUEI SHENGChen M.-Y.SZU-MIN HSIEHHsiao C.-F.JANN-TAY WANGCHIEN-CHING HUNGSHAN-CHWEN CHANG2020-12-292020-12-2920041058-4838https://www.scopus.com/inward/record.uri?eid=2-s2.0-2442638839&doi=10.1086%2f420744&partnerID=40&md5=094f64d054306bcbfde0c444715ae83fhttps://scholars.lib.ntu.edu.tw/handle/123456789/535466Between June 1994 and February 2003, a total of 111 human immunodeficiency virus (HIV)-infected patients with chronic hepatitis B virus (HBV) coinfection and 387 HIV-infected patients without HBV or hepatitis C virus coinfection were prospectively observed to assess the impact of HBV infection on outcomes of HIV-infected patients. After a median duration of observation of 25 months, coinfected patients were more likely to develop hepatitis (adjusted hazard ratio [AHR], 2.54; 95% confidence interval [CI], 1.69-3.82) and hepatic decompensation (adjusted odds ratio [AOR], 9.94; 95% CI, 1.89-52.35). Although similar proportions of the 2 patient groups had an increase in the CD4 count by ?100 × 106 cells/L (AOR, 0.78; 95% CI, 0.45-1.36) and development of new opportunistic illnesses (AOR, 0.94; 95% CI, 0.53-1.66), HBV-infected patients had an increased risk for virologic failure (AOR, 1.76; 95% CI, 1.03-2.99) and death (AHR, 1.71; 95% CI, 1.19-2.47) after highly active antiretroviral therapy was initiated.[SDGs]SDG3antiretrovirus agent; cotrimoxazole; itraconazole; lamivudine; proteinase inhibitor; RNA directed DNA polymerase inhibitor; adult; aged; article; cause of death; cholestasis; chronic hepatitis; clinical trial; confidence interval; controlled clinical trial; controlled study; endemic disease; female; hazard; hepatitis; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; highly active antiretroviral therapy; human; Human immunodeficiency virus; Human immunodeficiency virus infection; human tissue; infectious hepatitis; liver cirrhosis; liver disease; lymphocyte count; major clinical study; male; opportunistic infection; priority journal; risk; virology; Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Male; Middle Aged; Mortalityjournal article10.1086/42074415156487